Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
Articolo
Data di Pubblicazione:
2023
Citazione:
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders / D. Bagnasco, S. Nicola, E. Testino, L. Brussino, L. Pini, M. Caminati, F. Piccardo, R.F. Canevari, L. Melissari, A. Ioppi, L. Guastini, C. Lombardi, M. Milanese, F. Losa, M. Robbiano, L. De Ferrari, A.M. Riccio, G. Guida, M. Bonavia, D. Fini, F. Balbi, C. Caruso, P. Paggiaro, F. Blasi, E. Heffler, G. Paoletti, G.W. Canonica, G. Senna, G. Passalacqua. - In: BIOMEDICINES. - ISSN 2227-9059. - 11:9(2023), pp. 2424.1-2424.10. [10.3390/biomedicines11092424]
Abstract:
The efficacy mepolizumab in severe asthmatic patients is proven in the literature. Primarily
to study the effect of mepolizumab on exacerbations, steroid dependence, and the continuation of
efficacy in the long term. Secondarily to evaluate the effect of the drug on nasal polyps. Analyzing
data from SANI (Severe Asthma Network Italy) clinics, we observed severe asthmatic patients
treated with mepolizumab 100 mg/4 weeks, for a period of 3 years. 157 patients were observed.
Exacerbations were reduced from the first year (−84.6%) and progressively to 90 and 95% in the
second and third ones. Steroid-dependent patients decreased from 54% to 21% and subsequently to
11% in the second year and 6% in the third year. Patients with concomitant nasal polyps, assessed by
SNOT-22, showed a 49% reduction in value from baseline to the third year. The study demonstrated
the long-term efficacy of mepolizumab in a real-life setting.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
severe asthma; eosinophils; mepolizumab; CRSwNP; IL-5; real life; registry
Elenco autori:
D. Bagnasco, S. Nicola, E. Testino, L. Brussino, L. Pini, M. Caminati, F. Piccardo, R.F. Canevari, L. Melissari, A. Ioppi, L. Guastini, C. Lombardi, M. Milanese, F. Losa, M. Robbiano, L. De Ferrari, A.M. Riccio, G. Guida, M. Bonavia, D. Fini, F. Balbi, C. Caruso, P. Paggiaro, F. Blasi, E. Heffler, G. Paoletti, G.W. Canonica, G. Senna, G. Passalacqua
Link alla scheda completa: